secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001193125-24-113954
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre exchanges 90,992 Series A Preferred shares for 3.64M common shares
------------------------------------------------------------------------

- 90,992 shares of Series A Non-Voting Convertible Preferred Stock exchanged for 3,639,680 shares of common stock.
- Exchange closed April 25, 2024; common shares outstanding post-exchange: 40,279,414.
- Exemption from registration relied on Section 3(a)(9) of Securities Act; no commission paid.
- Counterparty is Fairmount Healthcare Fund II L.P.; conversion ratio based on existing conversion terms.
- Following exchange, 346,045 Series A Preferred and 271,625 Series B Preferred remain outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524113954/0001193125-24-113954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524113954/d787764d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-113954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer